Corcept to present new data on relacorilant in ovarian cancer at ESMO

Corcept Therapeutics (NASDAQ:CORT) is poised to present new Phase 3 ROSELLA trial data for its drug relacorilant in platinum-resistant ovarian cancer at ESMO in October 2025, a significant event following the FDA's acceptance of its New Drug Application for this indication, with a PDUFA date set for July 2026 based on improved survival rates. The company, which demonstrated strong financial health with robust cash flows and an Q2 2025 EPS beat despite a slight revenue miss, is targeting a market with high unmet medical need, contributing to analyst optimism reflected in price targets of $121-$145.

Analysis

Corcept Therapeutics (CORT) is advancing toward key clinical and regulatory milestones for its lead drug, relacorilant. The company is scheduled to present new Phase 3 ROSELLA trial data in platinum-resistant ovarian cancer at the ESMO Annual Meeting in October 2025, a significant catalyst given the data is featured as a late-breaking oral presentation. This follows the FDA's acceptance of the New Drug Application for this indication, setting a PDUFA date for July 11, 2026, and targeting a patient population with a high unmet need and a median survival of only 12 months. Financially, Corcept demonstrates a robust position with LTM revenue growth of 25.7%, a strong current ratio of 3.06, and minimal debt, ensuring it is well-capitalized to fund its pipeline. While Q2 2025 revenue of $194.4 million slightly missed expectations, this was offset by a significant 52.63% earnings per share beat. This solid fundamental backdrop, combined with a separate, earlier PDUFA date of December 30, 2025, for relacorilant in hypercortisolism, supports optimistic analyst price targets ranging from $121 to $145.

Key Decisions for Investors

• Investors should closely monitor the forthcoming ROSELLA trial data from the ESMO presentation in October 2025, as positive results are a critical near-term catalyst that could de-risk the path to the July 2026 PDUFA date for the ovarian cancer indication.
• The company's strong balance sheet, characterized by a 3.06 current ratio and minimal debt, alongside a significant Q2 EPS beat, suggests financial stability to fund its pipeline, mitigating concerns from the slight quarterly revenue miss.
• Consider the staggered regulatory catalysts, as the PDUFA date for hypercortisolism in December 2025 presents a potential near-term value inflection point and commercial validation ahead of the larger ovarian cancer market opportunity in mid-2026.